Spots Global Cancer Trial Database for alk+
Every month we try and update this database with for alk+ cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Expanded Access to Ensartinib for Participants With ALK+ NSCLC | NCT04146571 | Non-Small Cell ... ALK Gene Rearra... | Ensartinib | 18 Years - | Xcovery Holdings, Inc. | |
Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | NCT02299505 | Non-Small Cell ... | ceritinib | 18 Years - | Novartis | |
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib | NCT05948462 | Lung Cancer Non-small Cell ... | Lorlatinib Cisplatin or Ca... Pemetrexed | 18 Years - | SCRI Development Innovations, LLC | |
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas | NCT02048488 | Solid Tumors Lymphomas | TSR-011 | 18 Years - | Tesaro, Inc. | |
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib | NCT05948462 | Lung Cancer Non-small Cell ... | Lorlatinib Cisplatin or Ca... Pemetrexed | 18 Years - | SCRI Development Innovations, LLC |